Description: Argenica Therapeutics Limited researches and develops a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG007, a neuroprotective peptide candidate in pre-clinical trials for use in the protection of brain tissue against damage during a stroke. The company was incorporated in 2019 and is based in Nedlands, Australia.
Home Page: argenica.com.au
AGN Technical Analysis
117 Broadway
Nedlands,
WA
6009
Australia
Phone:
61 8 9329 3396
Officers
| Name | Title |
|---|---|
| Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. | CEO, MD & Director |
| Dr. Samantha South GAICD, MBA, Ph.D. | COO & Exec. Director |
| Ms. Emma Waldon | CFO & Company Sec. |
| Prof. Bruno Philip Meloni | Chief Scientific Officer |
| Dr. Meghan Thomas | Head of Clinical Devel. |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.3362 |
| Price-to-Sales TTM: | 167.74 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |